Abstract
Bleeding Oesophageal Varices (BOV) is a life-threatening condition that affects approximately 50% of cirrhotic patients. Vasoactive agents such as octreotide, vasopressin, somatostatin, and terlipressin are mainstays in the management BOV, with efficacy in attaining hemostasis in about 75% and 67% of patients at 48 hours and at 5 days, respectively. We conducted a cost-effectiveness analysis of terlipressin in the treatment of BOV from the payer’s perspective in the Philippine setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
